Sarah Cannon Research Institute | Strategic Alliance Partners

Todd Bauer, MD, associate director, Drug Development, principal investigator, Sarah Cannon Research Institute, discusses how phase I clinical trial programs are evolving and becoming more beneficial for patients with cancer.

Howard A. “Skip” Burris, MD, president of Clinical Operations and chief medical officer at Sarah Cannon Research Institute, a 2014 Giant of Cancer Care in Drug Development, discusses the biggest remaining challenges in treating patients with HER2-positive breast cancer.

Erika P. Hamilton, MD, director, Breast and Gynecologic Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses necessary research oncologists should begin conducting in the space of HER2-positive breast cancer.

Saeed Rafii, MD, PhD, medical director, Sarah Cannon Research Institute, United Kingdom, discusses novel immunotherapy approaches for the treatment of patients with bladder cancer.

Denise A. Yardley, MD, discusses two novel agents on the horizon for HER2-positive breast cancer.

Saeed Rafii, MD, PhD, MRCP, discusses the PD-L1 inhibitor durvalumab, the encouraging findings of it in Study 1108, and the evolving landscape of bladder cancer.

Howard A. "Skip" Burris, MD, offers insight on patient-reported outcomes from the MARIANNE trial and highlights exciting advancements in the neoadjuvant landscape of HER2-positive breast cancer.

During the past 2 years, there have been a number of advancements in the treatment of metastatic breast cancer that include the development of novel agents and new strategies in several disease settings, resulting in improved outcomes for patients.

Erika P. Hamilton, MD, discusses the significance of these trials and the impact ONT-380 may have on the treatment paradigm of HER2-positive breast cancer.

Howard A. “Skip” Burris III, MD, offers his views on key developments in the oncology field.

Jeffrey R. Infante, MD, discusses the fully human PD-L1 IgG1 antibody avelumab, which demonstrated clinical activity in patients with previously treated, recurrent/refractory ovarian cancer in a phase Ib open-label expansion trial.

Jeffrey R. Infante, MD, director, Drug Development Program, Sarah Cannon Research Institute, discusses the potential impact avelumab could have on the treatment of patients with ovarian cancer.

Hendrik-Tobias Arkenau, MD, PhD, executive medical director, Drug Development Unit, Sarah Cannon Research Institute-United Kingdom, discusses the overall survival results of the COMBI-d study, which examined the combination of dabrafenib and trametinib for the treatment of patients with unresectable or metastatic BRAF V600-mutated melanoma.

OncLive® will team with Sarah Cannon, the global cancer enterprise of Hospital Corporation of America, as it further expands its Strategic Alliance Partnership Program for raising awareness of cancer treatment and research.

For insight on the potential of ONT-380 in HER2-positive breast cancer, OncLive spoke with the lead author of the primary phase Ib analysis, Erika P. Hamilton, MD.

Saeed Rafii, MD, PhD, MRCP, medical director, Sarah Cannon Research Institute, discusses factors that influence clinical outcomes to olaparib in patients with BRCA1/2-mutant ovarian cancer.

Holli Dilks, PhD, Director, Personalized Medicine Operations Sarah Cannon Research Institute, discusses molecular profiling.

Ian Flinn, MD, PhD, director of the hematologic malignancies program at Sarah Cannon Research Institute, discusses how the approvals of idelalisib and ibrutinib will change treatment paradigms for chronic lymphocytic leukemia (CLL) and low-grade lymphoma.

Denise Yardley, MD, senior investigator, breast cancer research, Sarah Cannon Research Institute discusses the phase II FERGI study and how it can be applied to more than just breast cancer.

David Spigel, MD, director, Lung Cancer Research Program, Sarah Cannon Research Institute, discusses the development of onartuzumab for the treatment of patients with lung cancer.

Ian W. Flinn, MD, PhD, director, Hematologic Malignancies Research Program, Sarah Cannon Research Institute, discusses the DYNAMO Trial, which is looking at IPI-145 for the treatment of patients with refractory indolent non-Hodgkin lymphoma.

Ian W. Flinn, MD, PhD, director, Hematologic Malignancies Research Program, Sarah Cannon Research Institute, discusses IPI-145, an oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K- gamma.

The antibody-drug conjugate T-DM1 (ado-trastuzumab emtansine; Kadcyla) will have an impact on the entire spectrum of care for patients with metastatic HER2-positive breast cancer, resulting in a greater emphasis on patient selection protocols and testing.

Andrew Kennedy, MD, physician-in-chief, Radiation Oncology, Sarah Cannon, director, Radiation Oncology Research, Sarah Cannon Research Institute, discusses the utilization of radioactive microspheres.

Johanna Bendell, MD, discusses the rationale of a phase II trial looking at onartuzumab (MetMAb) and bevacizumab for patients with metastatic colorectal cancer (mCRC).

The recent approval of pertuzumab as part of a combination neoadjuvant treatment for patients with early-stage breast cancer has paved the way for wider use of the regimen in preoperative settings.

Johanna Bendell, MD, director of GI Cancer Research Program, associate director, Drug Development Program, Sarah Cannon Research Institute, discusses the anti-cancer stem cell antibody OMP-59R5 as a treatment option for patients with metastatic pancreatic cancer.

The PD-1 blocking antibody nivolumab continues to demonstrate sustained clinical activity in previously treated patients with advanced non-small cell lung cancer.

Johanna Bendell, MD, Director of GI Cancer Research Program, Associate Director, Drug Development Program, Sarah Cannon Research Institute, discusses the inhibition of heat shock protein 90 (Hsp90) in advanced solid tumors.

Johanna Bendell, MD, Director of GI Cancer Research Program, Associate Director, Drug Development Program, Sarah Cannon Research Institute, discusses c-MET inhibition in hepatocellular carcinoma.